78F0 Stock Overview
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Freeline Therapeutics Holdings plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.23 |
52 Week High | US$13.95 |
52 Week Low | US$3.12 |
Beta | 0.71 |
1 Month Change | 0% |
3 Month Change | -92.93% |
1 Year Change | -98.23% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
78F0 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 2.8% | -0.03% |
1Y | -98.2% | 38.7% | 5.5% |
Rentabilidad frente al sector: 78F0 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23.1%.
Rentabilidad vs. Mercado: 78F0 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.
Price Volatility
78F0 volatility | |
---|---|
78F0 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 78F0ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 78F0 en el último año.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 152 | Michael Parini | https://www.freeline.life |
Freeline Therapeutics Holdings plc Fundamentals Summary
78F0 fundamental statistics | |
---|---|
Market cap | €16.41m |
Earnings (TTM) | -€55.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 78F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
78F0 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$61.07m |
Earnings | -US$61.07m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -14.06 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 78F0 perform over the long term?
See historical performance and comparison